Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Isatuximab in combinazione con nuovi agenti in RRMM - Protocollo principale

16 novembre 2026 aggiornato da: Sanofi

Studio di fase 1-2 UMBRELLA che valuta Isatuximab con o senza desametasone in combinazione con nuovi agenti rispetto a Isatuximab con pomalidomide e desametasone nel mieloma multiplo recidivato o refrattario (RRMM) - Protocollo principale

The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Participants will continue study treatment until disease progression, death, unacceptable toxicity, participant request to stop treatment, Investigator decision, or study termination by the Sponsor i.e., up to Aapproximately 28 months.

Tipo di studio

Interventistico

Iscrizione (Stimato)

258

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Trial Transparency email recommended (Toll free number for US & Canada)
  • Numero di telefono: option 6 800-633-1610
  • Email: contact-us@sanofi.com

Luoghi di studio

    • New South Wales
      • Wollongong, New South Wales, Australia, 2500
        • Reclutamento
        • Investigational Site Number : 0360006
    • Victoria
      • Heidelberg, Victoria, Australia, 3084
        • Completato
        • Investigational Site Number : 0360003
      • Melbourne, Victoria, Australia, 3065
        • Reclutamento
        • Investigational Site Number : 0360002
      • Richmond, Victoria, Australia, 3121
        • Reclutamento
        • Investigational Site Number : 0360001
    • Seoul-teukbyeolsi
      • Seoul, Seoul-teukbyeolsi, Corea del Sud, 03722
        • Reclutamento
        • Investigational Site Number : 4100004
      • Seoul, Seoul-teukbyeolsi, Corea del Sud, 06351
        • Reclutamento
        • Investigational Site Number : 4100002
      • Seoul, Seoul-teukbyeolsi, Corea del Sud, 03080
        • Reclutamento
        • Investigational Site Number : 4100001
      • Seoul, Seoul-teukbyeolsi, Corea del Sud, 06591
        • Reclutamento
        • Investigational Site Number : 4100003
      • Lille, Francia, 59037
        • Reclutamento
        • Investigational Site Number : 2500002
      • Nantes, Francia, 44093
        • Reclutamento
        • Investigational Site Number : 2500001
      • Paris, Francia, 75013
        • Reclutamento
        • Investigational Site Number : 2500003
      • Paris, Francia, 75015
        • Reclutamento
        • Investigational Site Number : 2500004
      • Frankfurt, Germania, 60590
        • Reclutamento
        • Investigational Site Number : 2760006
      • Lübeck, Germania, 23562
        • Reclutamento
        • Investigational Site Number : 2760008
      • Athens, Grecia, 115 28
        • Reclutamento
        • Investigational Site Number : 3000001
      • Athens, Grecia, 106 76
        • Reclutamento
        • Investigational Site Number : 3000002
      • Jerusalem, Israele, 9112001
        • Reclutamento
        • Investigational Site Number : 3760002
      • Ramat Gan, Israele, 5262100
        • Reclutamento
        • Investigational Site Number : 3760003
      • Tel Aviv, Israele, 6423906
        • Reclutamento
        • Investigational Site Number : 3760001
    • Reggio Emilia
      • Meldola, Reggio Emilia, Italia, 47014
        • Reclutamento
        • Investigational Site Number : 3800001
      • Oslo, Norvegia, 0450
        • Reclutamento
        • Investigational Site Number : 5780001
    • Puerto Rico
      • Hato Rey, Puerto Rico, Porto Rico, 00917
        • Completato
        • Puerto Rico Medical Research Center- Site Number : 8400005
    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35233
        • Completato
        • University of Alabama at Birmingham- Site Number : 8400001
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Reclutamento
        • Winship Cancer Institute of Emory University- Site Number : 8400010
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60612
        • Completato
        • University of Illinois-Chicago - College of Medicine- Site Number : 8400007
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • Reclutamento
        • University of Michigan Health System - Ann Arbor- Site Number : 8400004
    • New York
      • Buffalo, New York, Stati Uniti, 14263
        • Reclutamento
        • Roswell Park Cancer Institute- Site Number : 8400008
    • Ohio
      • Columbus, Ohio, Stati Uniti, 43210
        • Reclutamento
        • The Ohio State University- Site Number : 8400012

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Participant must be 18 years of age inclusive or older.

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

  • Participants with relapsed or refractory MM who have received at least 2 prior lines of therapy for MM, including PIs and IMiDs (eg, Induction regimen with autologous stem cell transplant followed by maintenance is considered one line).

  • RRMM with measurable disease:

    • Serum M protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or
    • Urine M protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or
    • Serum free light chain (sFLC) MM without measurable M protein in serum or urine per previous criteria (serum Ig free light chain ≥10 mg/dL and abnormal serum Ig kappa lambda free light chain ratio <0.26 or >1.65).
  • Men or woman or childbearing potential should agree to use contraception.

  • Substudy 01, 06: Anti-CD38 therapy naïve or prior exposure to such drugs with a wash out of at least 12 months after the last dose. "Exposure" is defined as at least 2 cycles of therapy.

  • Substudies 02, 03: Anti-CD38 therapy naïve or prior exposure to such drugs without being refractory but with a wash out of at least 6 months after the last dose. "Refractory" is defined as progressing within 60 days of last dose of anti-CD38 targeting therapy.

  • Substudy 04: Anti-CD38 and anti-B cell maturation antigen (BCMA) therapy (if available) prior exposed participants with RRMM. For anti-CD38, "Exposure" is defined as at least 2 cycles of therapy. For anti-BCMA therapy if available, exposure is defined by at least 2 cycles of therapy.

  • Substudy 05: Participants with RRMM with at least 2 cycles of prior exposure to anti-CD38 therapy. For participants to whom BCMA targeted therapy is available (ie, approved in their region and can be reimbursed), at least 2 cycles of prior exposure to a BCMA targeted agent is mandatory.

Exclusion Criteria:

  • Primary systemic amyloid light chain amyloidosis, plasma cell leukemia, monoclonal gammopathy of undetermined significance, or smoldering myeloma.
  • Uncontrolled infection within 14 days prior to first study intervention administration.
  • Clinically significant cardiac (including valvular) or vascular disease within 3 months prior to first study intervention administration., eg, myocardial infarction, unstable angina, coronary (eg, coronary artery bypass graft, percutaneous coronary intervention) or peripheral artery revascularization, left ventricular ejection fraction <40%, heart failure New York Heart Association Classes III and IV, stroke, transient ischemic attack, pulmonary embolism, other thromboembolic event, or cardiac arrhythmia (Grade 3 or higher by NCI CTCAE Version 5.0).
  • Known acquired immunodeficiency syndrome-related illness or known human immunodeficiency virus (HIV) disease requiring antiviral treatment or active hepatitis A.
  • Uncontrolled or active hepatitis B virus (HBV) infection.
  • Active hepatitis C virus (HCV) infection.
  • Any of the following within 3 months prior to first study intervention administration: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease.
  • Second malignancy other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma, unless they are successfully treated with curative intent for more than 3 years before first study intervention administration.
  • Any anti-MM drug treatment within 14 days before first study intervention administration, including dexamethasone.
  • Participants with a contraindication to treatment.
  • Vaccination with a live vaccine 4 weeks before the start of the study.
  • Seasonal flu and COVID-19 vaccines that do not contain live virus are permitted.
  • Hemoglobin <8 g/dL.
  • Platelets <50 × 10^9/L.
  • Absolute neutrophil count <1.0 × 10^9/L.
  • Creatinine clearance <30 mL/min/1.73m2.
  • Total bilirubin >1.5 × ULN, except for known Gilbert syndrome in which direct bilirubin should be ≤2.5 × ULN.
  • Aspartate aminotransferase and/or alanine aminotransferase >3 × ULN.
  • Patients with grade 3 or 4 hypercalcemia.

Substudy 01:

-Malabsorption syndrome or any condition that can significantly impact the absorption of pomalidomide.

Substudy 02:

  • History of resected/ablated basal or squamous cell carcinoma (SCC) of the skin or carcinoma in situ of the cervix, or other local tumors, even if considered cured by local treatment.
  • Therapeutic doses of anticoagulants or antiplatelet agents within 7 days prior to the first dose of SAR439459.
  • Prothrombin time or INR >1.5 × upper limit of normal (ULN).

Substudy 03:

  • Current corneal epithelial disease except mild punctate keratopathy.
  • Patients who have received prior therapy with belantamab mafodotin.

Substudy 04:

  • Central nervous system or leptomeningeal disease.
  • Medical history of seizure.
  • Participants currently receiving hepatically metabolized narrow therapeutic index drugs (eg, digoxin, warfarin) if cannot be closely monitored.
  • Active, known, or suspected autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs), except controlled by replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc). The following are not exclusionary: vitiligo, childhood asthma that has resolved, psoriasis that does not require systemic treatment.
  • Prior allogeneic hematopoietic stem cell transplant (allo-HSCT).

Substudy 05:

- Participant unable to swallow tablets.

Substudy 06:

  • History of active autoimmune disorders.
  • History of autoimmune hemolytic anemia or autoimmune. thrombocytopenia.
  • Active graft versus host disease (GVHD) or ongoing immunosuppression for GVHD.
  • Prior allogenic hematopoietic stem cell transplant (allo-HSCT).
  • Patient with chronic active EBV infection.
  • Patients with known history of HLH.
  • Hemoglobin < 9 g/dL.
  • Prior therapy with any anti-CD47 or anti signal regulatory protein alpha agent.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Control Arm: isatuximab + pomalidomide + dexamethasone (Substudy 01)
  • Isatuximab, intravenous (IV) doseweekly (QW) × 4 weeks (Cycle 1), followed by every two weeks (Q2W) (subsequent cycles).
  • Pomalidomide dose by mouth daily Day 1 to Day 21.
  • Dexamethasone dose by mouth QW.

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

Altri nomi:
  • SAR650984
  • Sarclissa®

Pharmaceutical form: Tablet; Route of administration: Oral

Pharmaceutical form: Capsule; Route of administration: Oral

Altri nomi:
  • Pomalist®
Sperimentale: isatuximab + SAR439459 + dexamethasone (Substudy 02)

SAR439459 in combination with isatuximab and dexamethasone

Part 1:

2 dose levels (DLs) of IV SAR439459:

  • DL1 SAR439459 dose Q2W.
  • DL2 SAR439459 dose Q2W.
  • Isatuximab dose IV QW × 5 weeks (Cycle 1), followed by Q2W administrations (subsequent cycles).
  • Dexamethasone fixed dose and schedule: QW by mouth In Cycle 1, the first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab will be at Cycle 1 Day 8).

Part 2:

  • SAR439459 IV dose Q2W.
  • Isatuximab IV dose QW × 5 weeks (Cycle 1), followed by Q2W administrations (subsequent cycles).
  • Dexamethasone fixed dose and schedule: QW by mouth. In Cycle 1, the first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab will be at Cycle 1 Day 8).

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

Altri nomi:
  • SAR650984
  • Sarclissa®

Pharmaceutical form: Tablet; Route of administration: Oral

Pharmaceutical form: Solution for injection; Route of administration: Intravenous

Sperimentale: isatuximab + dexamethasone + belantamab mafodotin (Substudy 03)

Belantamab mafodotin in combination with isatuximab and dexamethasone

Part 1:

1 DL of IV belantamab mafodotin in Part 1 and de-escalation dose DL-1:

  • DL1 belantamab mafodotin IV dose QW4 or de-escalation dose DL-1 QW8
  • Isatuximab dose, IV QW × 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).
  • Dexamethasone fixed dose and schedule: QW by mouth.

Part 2:

  • Isatuximab IV dose QW × 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).
  • Belantamab mafodotin IV dose Q4W or Q8W
  • Dexamethasone fixed dose and schedule: QW by mouth.

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

Altri nomi:
  • SAR650984
  • Sarclissa®

Pharmaceutical form: Tablet; Route of administration: Oral

Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Altri nomi:
  • BLENREP®
Sperimentale: Isatuximab + pegenzileukin (Substudy 04)

Pegenzileukin in combination with isatuximab

Part 1- dose escalation:

  • Up to 3 DLs of IV pegenzileukin are planned to be evaluated:

    • DL1 will explore pegenzileukin at Q2W.
    • DL2 will explore pegenzileukin at Q2W.
    • DL3 will explore pegenzileukin at Q2W.
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles).

Part 1 - dose optimization:

  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles).
  • Pegenzileukin at potential doses (DL A and DL B) Q2W.

Part 2 (dose expansion):

  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles).
  • Pegenzileukin IV dose Q2W.

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

Altri nomi:
  • SAR650984
  • Sarclissa®

Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Altri nomi:
  • SAR444245
Sperimentale: Experimental: Isatuximab + Dexamethasone + Belumosudil (Substudy 05)

Isatuximab in combination with belumosudil and dexamethasone Part 1- dose escalation: During the first cycle, belumosudil will be evaluated in monotherapy during 2 to 4 weeks, then isatuximab and dexamethasone will be added, and continued for the subsequent cycles.

  • Belumosudil by mouth at Dose Level (DL) 1, DL2, DL3, and DL4
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth

Part 1- dose optimization:

  • Belumosudil at potential doses (DL A and DL B), daily by mouth
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth

Part 2- dose expansion:

  • Belumosudil dose daily, by mouth
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

Altri nomi:
  • SAR650984
  • Sarclissa®

Pharmaceutical form: Tablet; Route of administration: Oral

Pharmaceutical form: tablet; route of administration: oral

Altri nomi:
  • Rezurock
  • SAR445761,
Sperimentale: Isatuximab + evorpacept + dexamethasone (Substudy 06)

Isatuximab in combination with evorpacept and dexamethasone

Part 1- dose escalation:

  • Evorpacept IV dose Q2W
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth Part 1- dose optimization
  • Evorpacept IV at potential doses (DL A and DL B), Q2W
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth

Part 2- dose expansion:

  • Evorpacept IV dose Q2W
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

Altri nomi:
  • SAR650984
  • Sarclissa®

Pharmaceutical form: Tablet; Route of administration: Oral

Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Altri nomi:
  • ALX148

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Part 1 (dose finding, experimental substudies): Determination of recommended dose of novel agents in combination with isatuximab
Lasso di tempo: Through the end of cycle 1 (approximately 6 weeks)

Determination or confirmation of the dose will be based on: safety and tolerability in terms of TEAEs/SAEs, dose-limiting toxicity occurrence, and laboratory parameters available information on PK (if appropriate) and biomarkers.

Through the end of cycle 1 (approximately 6 weeks)
Part 2 (expansion, controlled experimental substudies): VGPR Rate (Rate of Very Good Partial Response Rate or Better)
Lasso di tempo: Up to approximately 28 months after the First patient in or scheduled assessment

VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Part 2 (expansion, independent experimental substudies): Overall Response Rate (ORR) in independent experimental substudies
Lasso di tempo: Up to approximately 28 months after the First patient in or scheduled assessment

ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Concentrazione di nuovi agenti (bracci sperimentali) e Isatuximab (Ctrough)
Lasso di tempo: Timepoint multipli durante il ciclo 1. Il ciclo è di 28 giorni.
Timepoint multipli durante il ciclo 1. Il ciclo è di 28 giorni.
Concentrazione massima osservata dopo la prima infusione (CMAX) per Belumosudil - sostanza 05
Lasso di tempo: Timepoint multipli durante il ciclo 1. Il ciclo è di 28 giorni.
Timepoint multipli durante il ciclo 1. Il ciclo è di 28 giorni.
Tempo per raggiungere CMAX (TMAX) per Belumosudil - Postudio 05
Lasso di tempo: Timepoint multipli durante il ciclo 1. Il ciclo è di 28 giorni.
Timepoint multipli durante il ciclo 1. Il ciclo è di 28 giorni.
Area sotto la concentrazione rispetto alla curva temporale calcolata usando il metodo trapezoidale da 0 a 8H (AUC0-8H) per il Belumosudil - Shopody 05
Lasso di tempo: Timepoint multipli durante il ciclo 1. Il ciclo è di 28 giorni.
Timepoint multipli durante il ciclo 1. Il ciclo è di 28 giorni.
Concentrazione massima osservata dopo la prima infusione (CMAX) per evorpacept - sostanza 06
Lasso di tempo: Timepoint multipli durante il ciclo 1. Il ciclo è di 28 giorni.
Timepoint multipli durante il ciclo 1. Il ciclo è di 28 giorni.
Tempo per raggiungere CMAX (TMAX) per evorpacept - sostanza 06
Lasso di tempo: Timepoint multipli durante il ciclo 1. Il ciclo è di 28 giorni.
Timepoint multipli durante il ciclo 1. Il ciclo è di 28 giorni.
Area sotto la concentrazione rispetto alla curva temporale calcolata usando il metodo trapezoidale sull'intervallo di dosaggio per evorpacept (AUC0-T)- ShOUMDY 06
Lasso di tempo: Timepoint multipli durante il ciclo 1. Il ciclo è di 28 giorni.
Timepoint multipli durante il ciclo 1. Il ciclo è di 28 giorni.
Part 1 (dose finding, experimental substudies): ORR
Lasso di tempo: Up to approximately 28 months after the First patient in or scheduled assessment

ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Part 2 (expansion, controlled experimental substudies): ORR
Lasso di tempo: Up to approximately 28 months after the First patient in or scheduled assessment

ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Part 1 (dose finding, experimental substudies): VGPR or better
Lasso di tempo: Up to approximately 28 months after the First patient in or scheduled assessment

VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Part 2 (expansion, independent experimental substudies): VGPR or better
Lasso di tempo: Up to approximately 28 months after the First patient in or scheduled assessment

VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Clinical benefit rate (CBR) in each treatment arm
Lasso di tempo: Up to approximately 28 months after the First patient in or scheduled assessment

CBR, defined as the proportion of participants with sCR, CR, VGPR, PR, or minimal response, according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Duration of Response (DOR) in each treatment arm
Lasso di tempo: Up to approximately 28 months after the First patient in or scheduled assessment

DOR, defined as the time from the date of the first response that is subsequently confirmed for patients achieving PR or better to the date of first documented PD or death, whichever happens first.

Up to approximately 28 months after the First patient in or scheduled assessment
Time to First Response (TT1R) in each treatment arm
Lasso di tempo: Up to approximately 28 months after the First patient in or scheduled assessment

TT1R, defined as the time from the date of first treatment to the date of first response (PR or better) that is subsequently confirmed.

Up to approximately 28 months after the First patient in or scheduled assessment
Time to Best Response (TTBR) in each treatment arm
Lasso di tempo: Up to approximately 28 months after the First patient in or scheduled assessment

TTBR, defined as the time from the date of first treatment to the date of first occurrence of best overall response (PR or better) that is subsequently confirmed.

Up to approximately 28 months after the First patient in or scheduled assessment
Number of participants with treatment emergent adverse events and serious adverse events in each treatment arm
Lasso di tempo: Up to approximately 28 months after the First patient in or scheduled assessment

Safety and tolerability assessed in terms of adverse events/SAEs, including second primary malignancies, laboratory parameters, vital signs, and findings from physical examination.

Up to approximately 28 months after the First patient in or scheduled assessment
Progression-free survival (PFS) in each treatment arm
Lasso di tempo: Up to approximately 28 months after the First patient in or scheduled assessment

PFS is defined as the time from the date of first treatment to disease progression based on the Investigator assessment according to 2016 IMWG criteria or death from any cause, whichever happens first.

Up to approximately 28 months after the First patient in or scheduled assessment
Overall Survival (OS) in each treatment arm
Lasso di tempo: Up to approximately 28 months after the First patient in or scheduled assessment

OS is defined as the time from the date of first treatment to death from any cause.

Up to approximately 28 months after the First patient in or scheduled assessment
Immunogenicity of isatuximab and novel agents
Lasso di tempo: Multiple timepoints up to approximately 28 months after the First patient in or scheduled assessment

Incidence of anti-drug antibodies (ADAs) for novel agents (experimental arms) and isatuximab.

Multiple timepoints up to approximately 28 months after the First patient in or scheduled assessment
Disease-specific HRQL will be assessed using the European Organization for Research and Treatment of Cancer (EORTC) core quality of life questionnaire (QLQ-C30)
Lasso di tempo: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

The EORTC QLQ-C30 will be used to assess cancer-specific HRQL, disease and treatment-related symptoms and impact of symptoms. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies).

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
Disease- and treatment-related quality of life will be assessed using the EORTC multiple myeloma module (QLQ-MY20) questionnaire
Lasso di tempo: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

The EORTC QLQ-MY20 will be used to measure myeloma-specific HRQL, disease and treatment-related symptoms and impact of symptoms. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies).

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
Global impact of side effects will be assessed using the Functional Assessment of Cancer Therapy (FACT-G) (GP5)
Lasso di tempo: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

A single item from the FACT-G GP5 will be used to assess the global impact of side effects. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies).

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
Estimate/Confirm established clinically meaningful change scores for clinical outcome assessments (COAs)/domain scores using the Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) scales
Lasso di tempo: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) scales will be utilized as anchors to estimate/confirm established clinically meaningful change scores for clinical outcome assessments (COAs)/domain scores. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies).

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
The intensity of skeletal-related events (SRE)- related bone pain will be assessed using the skeletal-related bone pain numeric rating scale (SRE-BP-NRS) for control and experimental arms -Substudy 02
Lasso di tempo: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

The SRE-BP-NRS) will be used to assess the intensity of SRE-related bone pain (on average and at its worst) for control arm only

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
SRE Incidence for control and experimental arms- Substudy 02
Lasso di tempo: Continuous throughout study assessment (up to approximately 28 months)

SRE incidence, defined as the proportion of participants who experienced pathological fracture, radiation to bone, spinal cord compression, or surgery to bone as a first bone event.

Continuous throughout study assessment (up to approximately 28 months)
Time to First Occurrence of SRE Assessment for control and experimental arms (Substudy 02)
Lasso di tempo: Continuous throughout study assessment (up to approximately 28 months)

Time to first occurrence of SRE is defined as time from the date of randomization to the occurrence of first SRE.

Continuous throughout study assessment (up to approximately 28 months)
Assessment of Health care resource utilization related with SREs for control and experimental arms -Substudy 02
Lasso di tempo: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at End of treatment and at first follow-up visit. The cycle is 28 days.

The Health Care Resource Use-SREs questionnaire (HCRU-SREs) will be used to assess the use of health care resources associated with these events.

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at End of treatment and at first follow-up visit. The cycle is 28 days.
To assess patient-reported visual functioning for experimental arm only -Substudy 03
Lasso di tempo: On Day1 Cycle 1, End of treatment and at first follow-up visit. The cycle is 28 days.

An NEI VFQ-25 will be used to assess patient-reported visual functioning.

On Day1 Cycle 1, End of treatment and at first follow-up visit. The cycle is 28 days.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Clinical Sciences & Operations, Sanofi

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

25 gennaio 2021

Completamento primario (Stimato)

13 settembre 2027

Completamento dello studio (Stimato)

20 aprile 2028

Date di iscrizione allo studio

Primo inviato

20 ottobre 2020

Primo inviato che soddisfa i criteri di controllo qualità

20 novembre 2020

Primo Inserito (Effettivo)

24 novembre 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • ACT16482
  • 2020-003024-16 (Numero EudraCT)
  • U1111-1244-2598 (Identificatore di registro: ICTRP)
  • 2024-514988-25 (Identificatore di registro: CTIS)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .